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cardiovascular mortality in persons with and
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Background: The prognostic utility of the ankle-brachial index (ABI) may be hampered in persons with diabetes due to
peripheral arterial stiffening in the ankles. Stiffening of toe arteries occurs infrequently in diabetes. We aimed to deter-
mine the nature of the relationship of the toe-brachial index (TBI) and ABI with cardiovascular disease (CVD) mortality
and to determine whether the associations are modiﬁed in individuals with diabetes.
Methods: Individuals with clinically suspected atherosclerotic peripheral arterial disease who underwent ABI and TBI
measurements in a vascular laboratory were monitored longitudinally for CVD mortality.
Results: Among 469 participants (89% men), the mean age was 68 6 9 years, and 36% had diabetes. The mean ABI was
0.836 0.28 and the mean TBI was 0.606 0.24. During median 7.0 years of follow-up, there were 158 CVD deaths. The
association of the ABI categories with CVD deaths differed in diabetic vs nondiabetic participants (P [ .002 for
interaction). In contrast, the association of the TBI categories with CVD deaths was similar, irrespective of diabetes status
(P [ .17 for interaction). Among diabetic patients, a U-shaped relationship was observed between ABI categories and
CVD death: those with low (<0.90) and high (>1.30) ABIs were both at higher risk than those with normal ABIs (range,
0.90-1.30). In nondiabetic patients, association of ABI categories with CVD death was linear, such that those with an
ABI >1.30 were at the lowest risk, whereas those with an ABI <0.90 were at higher risk. In contrast, the association of
TBI categories with CVD death was linear irrespective of diabetes status. High TBI categories consistently predicted low
risk, whereas risk was higher with progressively lower TBI categories.
Conclusions: Among diabetic individuals with clinically suspected peripheral arterial disease, those with low and high ABIs
are both at higher risk of CVDdeath. In contrast, a linear relationshipwas observed betweenTBI categories andCVDdeath
irrespective of diabetes status. Theseﬁndings suggest that stiffened ankle arteriesmay limit the predictive value of theABI in
individuals with diabetes, a limitation that may be overcome by measurement of the TBI. (J Vasc Surg 2014;60:390-5.)The ankle-brachial index (ABI), the principal diag-
nostic tool for peripheral arterial disease (PAD) screening,
reﬂects the ratio of systolic blood pressure at the ankle rela-
tive to the arm.1 However, its use is complicated in individ-
uals with diabetes, who frequently have calcium deposition
in the arterial media, a condition known as medial arterial
calciﬁcation (MAC). The most common anatomic location
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://dx.doi.org/10.1016/j.jvs.2014.02.008arterial stiffening, which results in vessels that are more
difﬁcult to occlude in the ankle and artiﬁcially elevates
the measured ankle systolic blood pressure. This leads to
falsely elevated ABIs that may render the ABI less sensitive
to the detection of ﬂow-limiting atherosclerotic PAD in in-
dividuals with diabetes.
Although MAC is common in the ankle arteries,2 the
toe arteries are usually spared.3 The toe-brachial index
(TBI) uses similar principles to the ABI, but reﬂects the
systolic pressures in the great toe to that in the arm.
Because MAC commonly spares the toes, the TBI may
be useful to detect atherosclerotic PAD in individuals
with MAC. Given concerns that the ABI may miss PAD
in individuals with diabetes, the American Diabetes Associ-
ation4 and the American Heart Association5 have both
recommended using TBI measurements to evaluate
atherosclerotic PAD in individuals with incompressible
ankle arteries or when the ABI is high (>1.30). Although
low ABI measurements are known to predict cardiovascular
disease (CVD) deaths in individuals with and without dia-
betes,6 it is uncertain whether the associations of high ABI
and CVD deaths differ by diabetes status and whether the
TBI measurement may provide useful information about
CVD risk when MAC is present.
Given that MAC and atherosclerotic PAD may coexist
in individuals with diabetes, MAC may render the ABI less
sensitive for detection of atherosclerotic PAD in individuals
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ABI measurements with risk of CVD death toward the
null. Because MAC is more common in diabetes, we hy-
pothesized that low TBI measurements would be more
strongly associated with CVD death than low ABI mea-
surement and that such differences would be more evident
in patients with diabetes.
METHODS
All individuals who participated in this study gave writ-
ten informed consent. The study protocol and consent
forms were approved by the University of California, San
Diego Investigational Review Board.
Study participants. Between 1990 and 1994, patients
who were seen in the previous 10 years for noninvasive
lower extremity arterial testing at the San Diego Veterans
Administration Medical Center or the University of
California, San Diego Medical Center (UCSDMC) vas-
cular laboratory were invited to participate in this study.
Of the 2265 candidates, 481 had died, and among the
remainder, 508 agreed to participate and returned for a
repeat study evaluation. Among these, we excluded those
with missing ABI measurements (n ¼ 2 [0.4%]), TBI mea-
surements (n ¼ 9 [1.8%]), and CVD risk factor data (n ¼
28 [6%]), resulting in ﬁnal analytic sample of 469 partici-
pants for this analysis.7,8
Vascular assessment. The ABI and TBI protocols
have been described in detail previously.7,8 Brieﬂy,
brachial, ankle, and toe pressures were measured bilaterally.
Blood pressure cuffs were placed on the arms, ankles, and
the bases of the big toes, and measurements were taken in a
temperature-controlled environment, with the participant
supine position, and after ten minutes of rest. Photo-
plethysmography was used to detect blood ﬂow at the third
ﬁnger for arm measurements and at the great toe for ABI
and TBI measurements. The ABI and TBI were computed
using the arm with the higher systolic pressure due to the
strong correlation between PAD and subclavian stenosis.9
The reproducibility of the ABI and TBI has been eval-
uated in prior studies. For the ABI, the 95% conﬁdence in-
tervals for reproducibility are between 0.10 and 0.15.10-12
Variability of the TBI is greater, reported anywhere from
the same as the ABI13 to about twice that of the ABI.11
The higher variability of the TBI may be due to higher sus-
ceptibility of toe arteries to vasoreactivity.14
CVD mortality. All participants were monitored
through December 31, 2001. Death was identiﬁed using
the Social Security Death Index, and death certiﬁcates
were obtained and coded by a certiﬁed nosologist using
International Classiﬁcation of Diseases (Ninth Edition)
codes. When the cause of death was coded 401 to 437.9,
excluding 412, participants were classiﬁed as having died
of CVD.
Other measurements. Age, sex, ethnicity, and smok-
ing history were self-reported. Participants were catego-
rized as current, former, or never smokers. Diabetes was
deﬁned as a fasting plasma glucose $126 mg/dL, use of
insulin, or use of oral hypoglycemic medications.Hypertension was deﬁned as systolic blood pressure
$140 mm Hg, diastolic pressure $90 mm Hg, or use of
antihypertensive medications. Body mass index was
calculated from values for weight (kg)/height (m2).
Dyslipidemia was categorized as use of lipid-lowering
drugs or a ratio of total cholesterol to high-density
cholesterol ratio of $5. Serum creatinine was measured
by the Jaffe method and combined with age, sex, and
ethnicity in the four-variable Modiﬁcation and Diet in
Renal Disease equation to estimate glomerular ﬁltration
rate (eGFR).15
Statistical analysis. We began by categorizing partic-
ipants into four groups based on clinical ABI cut points
of <0.60, 0.60 to 0.89, 0.90 to 1.30, and >1.30. We
compared differences in demographics and traditional
CVD risk factors across ABI categories using analysis of
variance for continuous variables and the c2 test or Fisher
exact test for categoric variables. Next, we categorized par-
ticipants into four categories based on TBI scores
of <0.40, 0.40 to 0.61, 0.62 to 1.08 and >1.08, such
that the percentage of participants in each TBI category
was similar to those in the corresponding ABI categories.
We used Cox proportional hazards models to evaluate
the associations of the ABI and TBI categories with time
to CVD death. The ABI category of 0.90 to 1.30 and
the TBI category of 0.62 to 1.08 served as the reference
category.
The initial model was unadjusted. A ﬁnal model was
adjusted for demographics and traditional CVD risk
factors, including age, sex, ethnicity, diabetes, smoking
(current, former, never), systolic blood pressure, blood
pressure medication use, total cholesterol, high-density li-
poprotein cholesterol, cholesterol medication use, eGFR,
and body mass index. Finally, we tested multiplicative
interaction terms (ABI  diabetes and TBI  diabetes)
in the fully adjusted models. When statistically signiﬁcant
interactions were detected, we evaluated the association
of ABI and TBI categories in diabetic and nondiabetic par-
ticipants separately. Analyses were conducted using STATA
SE 11.0 software (StataCorp LP, College Station, Tex).
P < .05 was considered statistically signiﬁcant for all ana-
lyses, including interaction terms.
RESULTS
The 469 study participants had a mean age of 68 6
9 years (range 39-100 years). A total of 417 (89%) were
men, reﬂecting heavy sampling from the Veterans Affairs
medical center, and 168 (36%) had diabetes. The mean
ABI was 0.83 6 0.28 and the mean TBI was 0.60 6
0.24. Classic claudication systems were present in 139 indi-
viduals (30%), and 15 (3%) had at least one leg with an
ABI <0.40, suggesting critical limb ischemia. CVD mortal-
ity risk did not differ signiﬁcantly across these groups. Base-
line characteristics by ABI categories are reported in
Table I. Compared with participants with normal ABI
(0.90-1.30), those in lower ABI categories were older,
more likely to have diabetes, hypertension, worse kidney
function, and lower TBI measurements.
Fig 1. Distribution of toe-brachial index (TBI) measurements by
ankle-brachial index (ABI) measurements.
Table I. Baseline characteristics by ankle-brachial index (ABI) categories
Variablea
ABI categories
P<0.60 0.60-0.89 0.90-1.30 >1.30
Patients 106 (22) 160 (34) 189 (40) 14 (3)
Age, years 70 6 8 70 6 8 66 6 10 65 6 9 <.01
Female 9 (8) 17 (11) 26 (14) 0 (0) .28
African American 5 (5) 8 (5) 5 (3) 0 (0) .55
Diabetes 49 (46) 55 (34) 52 (27) 12 (86) <.01
Hypertension 90 (85) 131 (81) 128 (68) 13 (92) <.05
Smoking <.05
Current 36 (25) 55 (38) 52 (36) 0 (0)
Former 58 (22) 86 (33) 108 (41) 8 (3)
Never 12 (18) 19 (28) 29 (44) 6 (9)
Body mass index, kg/m2 27 6 4 28 6 12 27 6 5 29 6 6 .67
Cholesterol, mg/dL
Total 214 6 44 212 6 41 204 6 37 199 6 47 .10
HDL 45 6 12 46 6 13 47 6 15 43 6 11 .72
eGFR, ml/min/1.73 m2 54 6 15 55 6 14 59 6 14 58 6 17 <.05
TBI 0.38 6 0.12 0.54 6 0.16 0.78 6 0.22 0.69 6 0.24 <.01
eGFR, Estimated glomerular ﬁltration rate; HDL, high density lipoprotein; TBI, toe-brachial index.
aCategoric data are presented as number (%) and continuous data as mean 6 standard deviation.
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function of ABI measurements. Although lower ABI scores
were generally associated with lower TBI scores, the distri-
bution of TBI scores was much more variable at higher
ABI levels, resulting in a nonlinear relationship at higher
levels.
During a median 7.0 years of follow-up, there were
158 CVD deaths, of which 75 (47%) occurred in patients
with diabetes. We created TBI categories to assign similar
numbers of participants to each TBI group as were
assigned to the corresponding ABI categories. Table II re-
ports the number of CVD deaths by TBI and ABI cate-
gories overall and also stratiﬁed by diabetes.
We observed that the association of ABI categories
with CVD death differed by diabetes status (P ¼ .002 for
interaction). Fig 2 shows Kaplan-Meier survival curves of
ABI (Fig 2, A) and TBI (Fig 2, B) groups with CVD death,
stratiﬁed by diabetes. Among nondiabetic individuals,
lower ABI levels were associated with a step-wise increase
in CVD death risk. In nondiabetic participants, no CVD
death events were observed in the group with ABI
>1.30, so the hazard ratios (HRs) were not calculable in
this group. In contrast, among participants with diabetes,
the group with ABI levels between 0.90 and 1.30 had
the lowest risk, whereas those with lower or higher ABI
had a comparatively higher risk of CVD death. The nature
of these relationships remained similar in Cox models
adjusted for age and sex and in fully adjusted models
(Table III).
We also observed that among individuals with ABI
scores <0.60, the HR for CVD death was stronger in
those without diabetes (HR, 3.81) than in those with
diabetes (HR, 2.83). To determine whether this part of
the distribution of ABI categories contributed to the
statistical effect modiﬁcation by diabetes status, weconducted a sensitivity analysis excluding individuals
with ABIs >1.30. In the remaining participants, the as-
sociation of ABI with CVD death remained statistically
signiﬁcantly different by diabetes status (P ¼ .03 for
interaction).
In contrast to the distinct nature of the relationship of
ABI categories with CVD death by diabetes status, the as-
sociation of TBI categories with CVD death was similar
irrespective of diabetes status (P ¼ .17 for interaction;
Fig 2, B). In both diabetic and nondiabetic participants,
stepwise lower TBI scores were associated with progres-
sively higher risk of CVD death. Participants in the highest
TBI score category (>1.08) were at the lowest risk of CVD
death irrespective of diabetes status. The nature of these as-
sociations was similar in models adjusted for age and sex
and in fully adjusted models (Table III).
Table II. Number of cerebrovascular disease (CVD) deaths by ankle-brachial index (ABI) and toe-brachial index (TBI)
category stratiﬁed by diabetes
Categories
All participants Diabetes No diabetes
Total, CVD death, Total, CVD death, Total, CVD death,
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
ABI
>1.30 14 (3) 7 (50) 12 (7) 7 (58) 2 (1) 0 (0)
0.90-1.30 189 (40) 37 (20) 52 (31) 14 (27) 137 (46) 23 (17)
0.60-0.89 160 (34) 55 (34) 55 (32) 25 (45) 105 (35) 30 (29)
<0.60 106 (23) 59 (56) 49 (29) 29 (59) 57 (19) 30 (53)
TBI
>1.08 14 (3) 2 (14) 5 (3) 1 (20) 9 (3) 1 (11)
0.62-1.08 196 (42) 45 (23) 51 (30) 17 (33) 145 (48) 28 (19)
0.40-0.61 157 (33) 59 (38) 70 (42) 34 (49) 87 (29) 25 (29)
<0.40 102 (22) 52 (51) 42 (25) 23 (55) 60 (20) 29 (48)
Fig 2. Kaplan-Meier curves of (A) ankle-brachial index (ABI) categories and (B) toe-brachial index (TBI) categories
with cardiovascular disease (CVD) mortality in (top panels) nondiabetic individuals compared with (bottom panels)
diabetic individuals. The shaded areas indicate the 95% conﬁdence intervals.
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Neither the ABI nor the TBI was associated with non-
CVD death in this cohort, and associations were similar
irrespective of diabetes status (P > .35 for both
interactions).DISCUSSION
Among individuals referred to a vascular laboratory
for suspected atherosclerotic PAD, we demonstrate that
the association of ABI measurements with CVD mor-
tality differs among those with and without diabetes.
Table III. Associations of ankle-brachial index (ABI) and toe-brachial index (TBI) categories with cardiovascular disease
(CVD) mortality overall and stratiﬁed by diabetes
Categories
All participants Diabetes No diabetes
Model 1a Model 2b Model 1a Model 2b Model 1a Model 2b
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ABIc
>1.30 2.99 (1.33-6.74) 1.81 (0.77-4.24) 2.47 (0.99-6.14) 1.80 (0.68-4.71) . .
0.90-1.30 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
0.60-0.89 1.99 (1.31-3.03) 1.92 (1.24-2.94) 2.21 (1.14-4.26) 2.03 (1.01-4.04) 1.72 (0.99-2.97) 1.66 (0.94-2.92)
<0.60 3.87 (2.56-5.85) 3.39 (2.18-5.27) 3.06 (1.61-5.81) 2.83 (1.42-5.61) 3.90 (2.25-6.74) 3.81 (2.13-6.81)
TBId
>1.08 0.49 (0.11-2.03) 0.47 (0.11-2.00) 0.39 (0.05-2.91) 0.39 (0.05-3.14) 0.54 (0.07-3.91) 0.44 (0.06-3.35)
0.62-1.08 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
0.40-0.61 1.62 (1.09-2.40) 1.36 (0.91-2.05) 1.53 (0.84-2.76) 1.44 (0.79-2.62) 1.24 (0.71-2.14) 1.14 (0.65-2.02)
<0.40 2.65 (1.77-3.96) 2.25 (1.47-3.43) 1.99 (1.06-3.74) 2.28 (1.15-4.55) 2.68 (1.58-4.52) 2.19 (1.26-3.80)
CI, Conﬁdence interval; HR, hazard ratio.
aAdjusted for age and sex.
bAdjusted for age, sex, ethnicity, diabetes, smoking (current, former, never), systolic blood pressure, blood pressure medication use, total cholesterol,
high-density lipoprotein cholesterol, lipid medication use, estimated glomerular ﬁltration rate, and body mass index.
cP ¼ .002 for interaction by diabetes status in the fully adjusted model.
dP ¼ .17 for interaction by diabetes status in the fully adjusted model.
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at a step-wise increased risk for CVD death, but a U-
shaped relationship was observed between the ABI and
CVD death in diabetic patients. In contrast, the associa-
tion of TBI categories with CVD death risk was linear,
irrespective of diabetes status. These ﬁndings may have
important implications for screening PAD among individ-
uals with diabetes.
Diabetes is a well-established risk factor for MAC,16
and MAC may falsely elevate the ABI.17 Prior studies by
our group in cohorts where ABI measurements and lower
limb X-ray images were both available simultaneously have
demonstrated that nearly all diabetic individuals with ABI
measurements >1.30 have arterial calciﬁcation on X-ray
imaging consistent with MAC.18 In the current study, we
found that individuals with diabetes and high ABI levels
were at higher risk for CVD death than those with
“normal” ABI levels (0.90-1.30). Similar ﬁndings were
not observed using the TBI, and MAC is known to spare
the toe arteries. We conclude that, when present, MAC
may decrease the sensitivity of the ABI for detection of
PAD and may also diminish the strength of the association
of the ABI with CVD death, a ﬁnding that may be over-
come using the TBI.
Even when we excluded participants with ABI scores
>1.30, we observed that the association of low ABI scores
with CVD death was stronger in nondiabetic individuals
than in diabetic individuals. This ﬁnding suggests that
MAC may be copresent and may increasing ABI scores
among diabetic individuals even when their ABI scores
are in the normal or low range, thus biasing the ABI-
CVD death association towards the null in diabetic
patients. Our ﬁndings support current recommendations
by the American Diabetes Association4 and American HeartAssociation,5 suggesting that diabetic patients with
elevated ABI or incompressible ankle arteries be referred
for additional vascular testing, including the TBI. In such
individuals, ﬁnding a normal or high ABI may not exclude
atherosclerotic PAD. Instead, many such individuals will
have MAC, which may preclude detection of atheroscle-
rotic PAD using the ABI. However, because we also
observed that the association of low ABI scores with
CVD death was weaker in diabetic patients compared
with nondiabetic patients, our ﬁndings suggest that even
diabetic patients with normal or low ABI scores may
beneﬁt from additional vascular testing with the TBI.
Such individuals may have more severe PAD and a higher
risk for CVD death than would be recognized by relying
solely on the ABI, likely because concomitant MAC is lead-
ing to higher ABI values than would have otherwise been
detected.
Although the association of the TBI with CVD death
was linear irrespective of diabetes status, the HRs linking
low TBI categories with CVD death were weaker compared
with the HRs linking low ABI categories with CVD death.
This may reﬂect differences in the reproducibility of the ABI
and TBI. The reproducibility of the ABI has been reported
between 0.10 and 0.15 in prior studies.12,19 In contrast, the
TBI evaluates systolic blood pressure in the great toe and
digital arteries and may be more susceptible to vasoconstric-
tion and increased resistance in response to colder ambient
temperature.19 Although the test-retest correlation of the
TBI is less well studied,20 if vasospasm and greater suscepti-
bility to temperature ﬂuctuations lowers its reproducibility,
this may have biased the association of the TBI with CVD
mortality towards the null and may have led to weaker asso-
ciations of the TBI with CVD mortality relative to the ABI
with the same outcome.13,14,19
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TBI may be because we set the intermediate TBI category
(0.62-1.08) as our reference group. This was done to pro-
vide a subgroup with comparable prevalence to those with
“normal” ABIs to allow comparisons across the two diag-
nostic tests. However, our results disclosed a linear rela-
tionship of the TBI with CVD deaths. Had we set the
highest TBI category as our reference group, the lowest
TBI group would have had stronger HRs for CVD mortal-
ity than the lowest ABI category.
Strengths of this study include its relatively large sample
size and long-term follow-up, concurrent availability of the
ABI and TBI measurements both made in a vascular labora-
tory setting, and a large number of participants with diabetes.
The study also has important limitations. Because we
studied participants who had been referred to our vascular
laboratory, the generalizability of the results to the general
population is uncertain. We recruited heavily from our Vet-
erans Affairs Medical Center, and most of the participants
were men. Although we demonstrated in prior studies
that a high ABI has high speciﬁcity for MAC in diabetic in-
dividuals,18 lower limb imaging conﬁrming the presence of
MAC was not available in this cohort.
CONCLUSIONS
Among individuals with clinically suspected atheroscle-
rotic PAD, the association of ABI measurements with CVD
mortality is U-shaped in diabetic patients and linear in
nondiabetic patients. In contrast, lower TBI scores were
linearly associated with CVD mortality irrespective of dia-
betes status. Peripheral arterial stiffness in individuals with
diabetes may limit the prognostic information obtained
from ABI measurements. Diabetic individuals with clini-
cally suspected PAD might beneﬁt from additional conﬁr-
matory tests for PAD irrespective of whether the ABI
measurements are low, normal, or elevated.
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